Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Hypercholesterolemia in the U.S.

Analysis of: Diabetes drug link to weak bones (news.bbc.co.uk)
-the relationship between avandia and ostoeporosis -implcations in clinical practice -implications for the future of avandia
Carlos Dujovne, MD, Professor of Medicine and Director
Carlos Dujovne, MD, Professor of Medicine and Director
OREGON HEALTH & SCIENCE UNIVERSITY - CC
Analysis of: New Phase 2 Study Shows That Liraglutide Leads to Significant Weight Loss in Obese People (pharmalive.com)
As past Principal Investigator in most clinical trials wit Orlistat I can offer a different interpretations of tthe resuls of the comparayive study just announced,as follows.1.The result on diabetes or glucose regulation were earlier with Liraglutide,possibly because it has specific antidiabetic(besides...
Howard Weintraub, MD, Clinical Director
New York University Medical Center
Analysis of: Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP (www.medicalnewstoday.com)
By restoring function in the late Na channel and hence improving diastolic function (amongst other things), Ranexa has worked terrifically in my patients with any evidence for diastolic dysfunction. This typically manifests with shortness of breath and can be associated with an elevated level...
Howard Weintraub, MD, Clinical Director
New York University Medical Center
November 8, 2007
Even more benefit.
Analysis of: Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP (www.medicalnewstoday.com)
The good news gets better as there is now data from MERLIN that corroborates the news from CARISA showing a reduction in HbGA1C that was significant.
Analysis of: Medtronic Voluntarily Suspends Distribution Of Sprint Fidelis® Defibrillation Leads (www.medicalnewstoday.com)
1) Data only shows trend towards higher lead fracture, not statistically significant on current numbers. 2) Medtronics did the "right thing". No attempts to hide data. 3) Number of potential claims should be minimal, as this is NOT a recall. Rather, more carefull monitoring of the already implanted...
October 10, 2007
Great potential
Analysis of: Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months (www.pipelinereview.com)
I think this drug has great potential for refractory high LDL and possibly in Acute Coronary Syndrome and CAD patients.
Analysis of: Sanofi aims to show there's still life in Acomplia (www.reuters.com)
Accomplia would be an effective new tool in management of obesity'A Dormant Volcano Waiting to Erupt' even amongst our youngsters,.Granted that it has adverseeffects i.e depression, suicidal ieation etc. However these disorders are frequently noted in Obese patients not using any meds it is also clear...
Analysis of: Galvus(R) receives European approval as new treatment for type 2 diabetes with broad range of indications (www.pipelinereview.com)
Galvus is now approved for use in all 27 countries of the European Union, plus Norway, Iceland, Brazil, and Mexico.  It is the first in it's class to be approved for combination therapy with all three of the most commonly prescribed oral diabetic agents--metformin, sulfonyureas,...
Analysis of: GlaxoSmithKline updates prescribing information for Avandia in the US (www.pipelinereview.com)
-reassuring clinical data -severe PR damage
Analysis of: Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients (www.pipelinereview.com)
-Key therapeutic class -difficult competition

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next61 to 70 of 146

Analytics


Generated at 2009-01-07T19:00:58.307